pyrazinamide has been researched along with HIV in 11 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lopinavir-ritonavir forms the backbone of current first-line antiretroviral regimens in young HIV-infected children." | 7.88 | Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. ( de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J, 2018) |
| " We included studies in children aged <18 years being treated for drug-susceptible tuberculosis with rifampicin (RIF), pyrazinamide, isoniazid, and ethambutol." | 5.41 | Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis. ( Béranger, A; Gegia, M; Linh, NN; Mirzayev, F; Mohamed, A; Nahid, P; Radtke, K; Savic, RM; Schumacher, SG; Solans, BP, 2023) |
| "We used nonlinear mixed-effects modeling to characterize the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide, and investigated the association of human immunodeficiency virus (HIV), antiretroviral therapy (ART), drug formulation, age, and body size with their pharmacokinetics." | 4.31 | Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis. ( Aarnoutse, R; Chabala, C; Cotton, MF; Denti, P; Galileya, LT; Gibb, D; Hesseling, A; Lee, J; McIlleron, H; Njahira Mukui, I; Rabie, H; Turkova, A; Wasmann, RE; Zar, H, 2023) |
| "Lopinavir-ritonavir forms the backbone of current first-line antiretroviral regimens in young HIV-infected children." | 3.88 | Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. ( de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J, 2018) |
| "There are limited pharmacokinetic data for use of the first-line antituberculosis drugs during infancy (<12 months of age), when drug disposition may differ." | 2.82 | Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ( Bekker, A; Donald, PR; Draper, HR; Hesseling, AC; McIlleron, HM; Murray, S; Schaaf, HS; van der Laan, L; Wiesner, L, 2016) |
| "The frequency of late recurrences following treatment completion has not been well-studied." | 1.37 | When tuberculosis comes back: who develops recurrent tuberculosis in california? ( Deriemer, K; Flood, JM; Pascopella, L; Watt, JP, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Solans, BP | 1 |
| Béranger, A | 1 |
| Radtke, K | 1 |
| Mohamed, A | 1 |
| Mirzayev, F | 1 |
| Gegia, M | 1 |
| Linh, NN | 1 |
| Schumacher, SG | 1 |
| Nahid, P | 1 |
| Savic, RM | 1 |
| Galileya, LT | 1 |
| Wasmann, RE | 1 |
| Chabala, C | 1 |
| Rabie, H | 1 |
| Lee, J | 1 |
| Njahira Mukui, I | 1 |
| Hesseling, A | 1 |
| Zar, H | 1 |
| Aarnoutse, R | 1 |
| Turkova, A | 1 |
| Gibb, D | 1 |
| Cotton, MF | 2 |
| McIlleron, H | 3 |
| Denti, P | 3 |
| Schutz, C | 1 |
| Chirehwa, M | 1 |
| Barr, D | 1 |
| Ward, A | 1 |
| Janssen, S | 1 |
| Burton, R | 1 |
| Wilkinson, RJ | 1 |
| Shey, M | 1 |
| Wiesner, L | 3 |
| Maartens, G | 1 |
| Meintjes, G | 2 |
| van der Laan, LE | 1 |
| Garcia-Prats, AJ | 1 |
| Schaaf, HS | 3 |
| Tikiso, T | 1 |
| de Kock, M | 1 |
| Winckler, J | 1 |
| Norman, J | 1 |
| Hesseling, AC | 2 |
| Zhao, Y | 1 |
| Fox, T | 1 |
| Manning, K | 1 |
| Stewart, A | 1 |
| Tiffin, N | 1 |
| Khomo, N | 1 |
| Leslie, J | 1 |
| Boulle, A | 1 |
| Mudaly, V | 1 |
| Kock, Y | 1 |
| Wasserman, S | 1 |
| Walsh, KF | 1 |
| Souroutzidis, A | 1 |
| Vilbrun, SC | 1 |
| Peeples, M | 1 |
| Joissaint, G | 1 |
| Delva, S | 1 |
| Widmann, P | 1 |
| Royal, G | 1 |
| Pry, J | 1 |
| Bang, H | 1 |
| Pape, JW | 1 |
| Koenig, SP | 1 |
| Bekker, A | 1 |
| Draper, HR | 1 |
| van der Laan, L | 1 |
| Murray, S | 1 |
| Donald, PR | 1 |
| McIlleron, HM | 1 |
| Pascopella, L | 1 |
| Deriemer, K | 1 |
| Watt, JP | 1 |
| Flood, JM | 1 |
| Shaweno, D | 1 |
| Worku, A | 1 |
| Tortajada, C | 1 |
| Martínez-Lacasa, J | 1 |
| Sánchez, F | 1 |
| Jiménez-Fuentes, A | 1 |
| De Souza, ML | 1 |
| García, JF | 1 |
| Martínez, JA | 1 |
| Caylà, JA | 1 |
| Gie, RP | 1 |
| van Rie, A | 1 |
| Seifart, HI | 1 |
| van Helden, PD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)[NCT01637558] | Phase 4 | 200 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pyrazinamide and HIV
| Article | Year |
|---|---|
Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Ethambutol; HIV; HIV Infections; Humans; Isoniazid; | 2023 |
2 trials available for pyrazinamide and HIV
| Article | Year |
|---|---|
Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.
Topics: Anti-Bacterial Agents; Area Under Curve; Coinfection; Drug Dosage Calculations; Ethambutol; Female; | 2016 |
Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus?
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Child; Child, Preschool; Dose-Response Relationship, | 2005 |
8 other studies available for pyrazinamide and HIV
| Article | Year |
|---|---|
Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; HIV; HIV Infections; Huma | 2023 |
Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis.
Topics: Adult; Antitubercular Agents; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Pyrazinamide; Tu | 2020 |
Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
Topics: Anti-HIV Agents; Antitubercular Agents; Child; Drug Administration Schedule; Drug Combinations; Drug | 2018 |
Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
Topics: Adult; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Resistance, Multiple, Bacterial; E | 2019 |
Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethiona | 2019 |
When tuberculosis comes back: who develops recurrent tuberculosis in california?
Topics: Adult; Antitubercular Agents; California; Drug Therapy, Combination; Female; HIV; HIV Infections; Hu | 2011 |
Tuberculosis treatment survival of HIV positive TB patients on directly observed treatment short-course in Southern Ethiopia: a retrospective cohort study.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Drug Administration Schedule; Fem | 2012 |
Second episode of tuberculosis in an HIV-infected child: relapse or reinfection?
Topics: AIDS-Related Opportunistic Infections; Amoxicillin-Potassium Clavulanate Combination; Antibiotics, A | 2000 |